CTSO Cytosorbents Corp

Price (delayed)

$8.33

Market cap

$360.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.21

Enterprise value

$292.84M

Sector: Healthcare
Industry: Medical Devices

Highlights

The quick ratio has soared by 172% YoY
The debt has dropped by 97% year-on-year and by 21% since the previous quarter
CTSO's EPS has soared by 61% YoY but it is down by 5% from the previous quarter
CTSO's net income has surged by 52% year-on-year but it is down by 9% since the previous quarter
The equity has declined by 2.5% since the previous quarter

Key stats

What are the main financial stats of CTSO
Market
Shares outstanding
43.32M
Market cap
$360.85M
Enterprise value
$292.84M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.66
Price to sales (P/S)
8.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.83
Earnings
Revenue
$42.9M
EBIT
-$8.77M
EBITDA
-$8.14M
Free cash flow
-$5.65M
Per share
EPS
-$0.21
Free cash flow per share
-$0.13
Book value per share
$1.79
Revenue per share
$0.99
TBVPS
$2.02
Balance sheet
Total assets
$87.48M
Total liabilities
$10.22M
Debt
$461,064
Equity
$77.26M
Working capital
$69.88M
Liquidity
Debt to equity
0.01
Current ratio
8.16
Quick ratio
7.53
Net debt/EBITDA
8.36
Margins
EBITDA margin
-19%
Gross margin
73.4%
Net margin
-19.9%
Operating margin
-25%
Efficiency
Return on assets
-10.3%
Return on equity
-13.1%
Return on invested capital
-73.3%
Return on capital employed
-11.3%
Return on sales
-20.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTSO stock price

How has the Cytosorbents stock price performed over time
Intraday
2.46%
1 week
-0.95%
1 month
-9.95%
1 year
-19.52%
YTD
4.52%
QTD
-4.03%

Financial performance

How have Cytosorbents's revenue and profit performed over time
Revenue
$42.9M
Gross profit
$31.48M
Operating income
-$10.74M
Net income
-$8.55M
Gross margin
73.4%
Net margin
-19.9%
The net margin has surged by 68% year-on-year but it has declined by 4.2% since the previous quarter
Cytosorbents's operating margin has surged by 59% YoY
The gross profit has surged by 54% year-on-year and by 5% since the previous quarter
CTSO's net income has surged by 52% year-on-year but it is down by 9% since the previous quarter

Growth

What is Cytosorbents's growth rate over time

Valuation

What is Cytosorbents stock price valuation
P/E
N/A
P/B
4.66
P/S
8.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.83
CTSO's EPS has soared by 61% YoY but it is down by 5% from the previous quarter
CTSO's P/B is 83% lower than its 5-year quarterly average of 26.6 and 36% lower than its last 4 quarters average of 7.1
The equity has declined by 2.5% since the previous quarter
Cytosorbents's revenue has surged by 51% YoY and by 4.6% QoQ
The stock's price to sales (P/S) is 30% less than its 5-year quarterly average of 11.7 and 11% less than its last 4 quarters average of 9.2

Efficiency

How efficient is Cytosorbents business performance
The ROE has soared by 92% YoY and by 14% from the previous quarter
The ROA has soared by 81% YoY and by 6% QoQ
CTSO's ROS has soared by 67% YoY but it is down by 8% from the previous quarter
The ROIC has contracted by 42% from the previous quarter but it has grown by 20% YoY

Dividends

What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTSO.

Financial health

How did Cytosorbents financials performed over time
The quick ratio has soared by 172% YoY
CTSO's current ratio has surged by 150% year-on-year
The debt is 99% smaller than the equity
The debt to equity has dropped by 99% year-on-year
The debt has dropped by 97% year-on-year and by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.